Case Control Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2020; 8(22): 5529-5534
Published online Nov 26, 2020. doi: 10.12998/wjcc.v8.i22.5529
Osteoprotegerin, interleukin and hepatocyte growth factor for prediction of diabetes and hypertension in the third trimester of pregnancy
Su-Jing Huang, Hong-Wei Wang, Hai-Fang Wu, Qiu-Yuan Wei, Shu Luo, Lin Xu, Hong-Qiong Guan
Su-Jing Huang, Hong-Wei Wang, Hai-Fang Wu, Qiu-Yuan Wei, Shu Luo, Lin Xu, Hong-Qiong Guan, Department of Obstetrics, The Second Affiliated Hospital of Hainan Medical College, Haikou 570311, Hainan Province, China
Author contributions: Huang SJ and Wang HW contributed equally to this manuscript; Huang SJ, Wang HW, Wu HF, Wei QY, Luo S, Xu L and Guan HQ collected data and wrote the manuscript; Guan HQ reviewed the manuscript.
Supported by Hainan Province Major Program of Science and Technology Projects 2017, No. ZDKJ2017007.
Institutional review board statement: The study was reviewed and approved by Institutional Review Board of The Second Affiliated Hospital of Hainan Medical College.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare they have no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Qiong Guan, MD, Chief Physician, Department of Obstetrics, The Second Affiliated Hospital of Hainan Medical College, No. 48 Baishuitang Road, Haikou 570311, Hainan Province, China. guanhq1962@163.com
Received: September 1, 2020
Peer-review started: September 1, 2020
First decision: September 13, 2020
Revised: September 24, 2020
Accepted: October 1, 2020
Article in press: October 1, 2020
Published online: November 26, 2020
Processing time: 85 Days and 5.1 Hours
Abstract
BACKGROUND

Gestational diabetes mellitus (GDM) raises the risk of high blood pressure and may cause a series of life-threatening complications in pregnant women. Screening and management of GDM and gestational hypertension (GH) in pregnancy helps to control and reduce these risks and prevent adverse effects on mothers and their fetuses. Currently, the majority criteria used for screening of diabetes mellitus is oral glucose tolerance tests, and blood pressure test is usually used for the screening and diagnosis of hypertension. However, these criteria might not anticipate or detect all GDM or GH cases. Therefore, new specific predictive and diagnostic tools should be evaluated for this population. This study selected three biomarkers of osteoprotegerin (OPG), interleukin (IL) and hepatocyte growth factor (HGF) for GDM and GH predication and diagnosis.

AIM

To explore the feasibility of changes in placental and serum OPG, IL and HGF as tools for prediction and diagnosis of diabetes and hypertension in pregnant women.

METHODS

From January 2018 to January 2019, 44 pregnant women with GDM and GH were selected as an observation group, and 44 healthy pregnant women were selected as a control group in the same period. Serum OPG, IL and HGF were compared between the two groups.

RESULTS

The levels of OPG and HGF in the observation group were lower than in the control group, and the level of IL-1β was higher in the observation group than in the control group (all P < 0.05). Furthermore, OPG and HGF were negatively associated with gestational diabetes and gestational hypertension, while IL-1β was positively associated with GDM complicated with GH (all P < 0.05).

CONCLUSION

The evaluation of serum OPG, HGF and IL-1β levels in patients with coexistent gestational diabetes complicated with hypertension can predict the degree of disease and play an important role in the follow-up treatment and prognosis prediction.

Keywords: Third trimester of pregnancy; Osteoprotegerin; Interleukin; Hepatocyte growth factor; Gestational diabetes mellitus; Gestational hypertension

Core Tip: Gestational diabetes mellitus (GDM) and gestational hypertension (GH) are associated with serious and long-term feto-maternal and neonatal outcomes compared to normal pregnancies. Although oral glucose tolerance tests and blood pressure tests were accepted criteria for screenings of GDM and GH, these criteria might not anticipate or detect all GDM or GH cases. Biomarkers may serve as adjunct predictors for GDM and GH. The present study explored osteoprotegerin, interleukin and hepatocyte growth factor for prediction of GDM and GH.